Camp4 Therapeutics CAMP 深 滬
已收盤 08-07 16:00:00 美东时间
4.24
-0.260
-5.78%
華盛通- 最 高4.60
- 今 開4.58
- 成交量 9.52万股
- 最 低 4.15
- 昨 收 4.50
- 總市值 2.66亿
- 52周最高 7.75
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 1.41
- 委 比 -36.71%
- 總股本 6272.16万
- 歷史最高 12.30
- 量 比 0.35
- 振 幅 10.00%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CAMP4 Therapeutics Secures $50 Million Private Financing
CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2...
08-04 19:29
CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025 CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWS...
07-27 19:05
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
CAMP4 Therapeutics received clearance from Australia's TGA and HREC to initiate a Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder. This approval marks a significant step toward the first-in-human study for this condition, which currently has no approved treatments. The clearance also enables the company to raise up to $50 million through a second closing of its private placement, with notab...
07-27 11:00
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Corporation granted a non-qualified stock option to a newly hired employee, allowing the purchase of 8,000 shares at $4.21 per share. The option vests over four years, with 25% of shares vesting after the first year and the rest vesting monthly. The grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the Company's 2026 Inducement Plan. CAMP4 focuses on developing RNA-targeting therapeutics to treat genetic diseases ...
07-17 20:05
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan
J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corporation to a Bu...
06-23 20:37
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics granted non-qualified stock options to three new employees on June 15, 2026, under Nasdaq Rule 5635(c)(4). The options, totaling 39,000 shares with an exercise price of $3.96, vest over four years. CAMP4 focuses on developing RNA-targeting therapeutics to treat genetic diseases by amplifying healthy protein levels.
06-19 20:05
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Jean Ann Salisbury upgraded Exxon Mobil Corp (NYSE:XOM) from Neutral to...
06-16 20:01
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
